Related Experiment Video
Updated: Jul 28, 2026

Measurement of Heme Synthesis Levels in Mammalian Cells
Published on: July 9, 2015
Heme oxygenase-1 induction and mitochondrial iron sequestration in astroglia exposed to amyloid peptides
1Bloomfield Centre for Research in Aging, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada.
Abstract:
The mechanisms responsible for pathological iron deposition and mitochondrial insufficiency that have been documented in the brains of Alzheimer (AD) patients remain poorly understood. In the present study, we demonstrate that low-micromolar concentrations of amyloid1-40 (A40) and amyloid 1-42 (A42), peptides implicated in the pathogenesis of AD, increase levels of heme oxygenase-1 (HO-1) mRNA and protein in cultured rat astroglia. Furthermore, 6 days of exposure to amyloid augments the sequestration of 55FeCl3-derived iron by astroglial mitochondria without affecting the disposition of this metal in whole-cell and lysosomal compartments. Mitochondrial iron deposition was not observed in the amyloid-treated glia when diferric-transferrin served as the metal donor. We had previously shown that inhibitors of HO-1 and the mitochondrial permeability transition pore (MTP) block the uptake of mitochondrial iron in astrocytes exposed to the pro-oxidant effects of dopamine and several pro-inflammatory cytokines. Similarly, in the current study, amyloid-induced mitochondrial iron trapping was significantly attenuated by co-administration of the HO-1 transcriptional suppressor, dexamethasone (DEX) or the MTP blocker, cyclosporin A (CSA). Thus, the marked enhancement of HO-1 expression previously demonstrated in AD-affected neurons and astroglia may transduce amyloid (oxidative) stress into the abnormal patterns of iron deposition and mitochondrial insufficiency characteristic of this disease. Finally, in experiments employing cytotoxic concentrations of A40, we provide evidence that inhibition of HO-1 transcription and related mitochondrial iron deposition may be an important mechanism by which DEX protects tissues subjected to amyloid stress.
Insights
Alzheimer's disease (AD) involves brain iron buildup and mitochondrial issues. Amyloid peptides increase heme oxygenase-1 (HO-1), leading to iron accumulation in mitochondria, contributing to AD pathology.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Alzheimer's disease (AD) is characterized by pathological iron deposition and mitochondrial dysfunction.
- The precise mechanisms linking amyloid peptides to these brain changes are not fully understood.
Purpose of the Study:
- To investigate how amyloid peptides (A40 and A42) affect iron metabolism and mitochondrial function in brain cells.
- To explore the role of heme oxygenase-1 (HO-1) in amyloid-induced mitochondrial iron sequestration.
Main Methods:
- Primary rat astroglia cultures were exposed to amyloid peptides (A40, A42).
- Levels of heme oxygenase-1 (HO-1) mRNA and protein were measured.
- Iron sequestration by astroglial mitochondria was assessed using 55FeCl3.
- The effects of HO-1 transcriptional suppressor (dexamethasone) and mitochondrial permeability transition pore (MTP) blocker (cyclosporin A) were evaluated.
Main Results:
- Amyloid peptides increased HO-1 expression in astroglia.
- Amyloid exposure enhanced iron sequestration by astroglial mitochondria, but not in whole cells or lysosomes.
- Mitochondrial iron trapping was dependent on the iron donor, with no effect observed when using diferric-transferrin.
- Amyloid-induced mitochondrial iron sequestration was significantly reduced by dexamethasone and cyclosporin A.
Conclusions:
- Enhanced HO-1 expression may mediate the effects of amyloid stress, leading to abnormal iron deposition and mitochondrial dysfunction in Alzheimer's disease.
- Inhibition of HO-1 transcription and mitochondrial iron deposition by dexamethasone may protect against amyloid toxicity.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Hepatic Encephalopathy

